Close Menu

NEW YORK — Arcis Biotechnology has signed an agreement to license its nucleic acid sample preparation and preservation technology to Spanish microRNA diagnostics developer Mirnax Biosens, the companies said today.

Under the terms of the deal, Mirnax will use Arcis' technology to improve the stability of miRNA biomarkers for early disease detection. The firms will also work together to develop a microfluidic device that integrates their respective technologies.

Additional terms were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.